WOBURN, Mass., and SANTA CLARA, Calif., May 20, 2010 (BUSINESS WIRE) -- BIOCIUS Life Sciences, Inc. and Agilent Technologies Inc. /quotes/comstock/13*!a/quotes/nls/a (A 31.34, +0.30, +0.97%) today announced the launch of the RF360 High Resolution System for high-throughput screening of in vitro ADME assays. Combining the accurate mass capabilities of Agilent’s time-of-flight (TOF) mass spectrometers and the unprecedented sample processing speed of RapidFire(R) technology, the instrument revolutionizes in vitro ADME analysis by eliminating the method development bottleneck in drug discovery.
